Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC

NCT ID: NCT06861894

Last Updated: 2025-05-15

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 164 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-07-31
• Study Completion Date: 2029-03-31

Brief Summary

In this prospective trial, patients demonstrating clinical complete response (cCR) as determined by a standard response assessment protocol (incorporating clinical and molecular diagnostic methods) will be offered organ-sparing management following neoadjuvant therapy with adebrelimab (anti-PD-L1) concurrent with chemoradiotherapy. The primary endpoint is 2-year overall survival rate in this watch-and-wait cohort.

Conditions

Esophageal Squamous Cell Carcinoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

perioperative treatment with adebrelimab and CRT

Group Type: EXPERIMENTAL

Adebrelimab and nab-paclitaxel and carboplatin

Intervention Type: DRUG

Adebrelimab combined with nab-paclitaxel and carboplatin as neoadjuvant therapy

Radiation

Intervention Type: RADIATION

concurrent chemoradiotherapy

standard oesophagectomy

Intervention Type: PROCEDURE

standard oesophagectomy

active surveillance

Intervention Type: OTHER

active surveillance

Interventions

Adebrelimab and nab-paclitaxel and carboplatin

Adebrelimab combined with nab-paclitaxel and carboplatin as neoadjuvant therapy

Intervention Type: DRUG

Radiation

concurrent chemoradiotherapy

Intervention Type: RADIATION

standard oesophagectomy

standard oesophagectomy

Intervention Type: PROCEDURE

active surveillance

active surveillance

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Subjects signed the informed consent and volunteered to participate in the study.

2. Esophageal squamous cell carcinoma confirmed by histology or cytology.

3. Thoracic esophageal squamous cell carcinoma confirmed by CT or pet-CT, which is classified as cII-III (AJCC 8th).

4. Expect to have R0 resection

5. In age from 18 to 75.

6. ECOG PS: 0~1.

7. Have not received any anti-tumor treatment for esophageal cancer in the past, including radiotherapy, chemotherapy, surgery, etc.

8. No contraindications to surgery.

9. Has sufficient organ function including (1) Blood routine: NE≥1.5×109/L; PLT≥100×109/L; HGB≥90 g/L (2)Comprehensive Metabolic Panel: bilirubin≤ 1.5×ULN; ALT≤2.5×ULN; AST≤2.5×ULN; sCr≤1.5×ULN or CrCl≥50 mL/min（Cocheroft-Gault) (3) Coagulation function: INR≤1.5; APTT≤1.5×ULN

10. Women of childbearing age must undergo a serological pregnancy test within 72 hrs before first administration. Women of childbearing age, or male subjects with childbearing age female partners, must take contraceptive measures from the first dose to three months after last administration.

11. Good compliance, willing to comply with follow-up schedules.

Exclusion Criteria

1. Subjects have received or are receiving any of:

1. anti-tumor interventions such as radiotherapy, chemotherapy, or other medications.

2. immunosuppressants or systemic glucosteroids (prednisone equivalence> 10mg/d) within 2 weeks before the first administration, inhaled or topical use of glucosteroids (prednisone equivalence>10mg/d) is allowed if no known active autoimmune disease.

3. live vaccine within 4 weeks before the first administration.

4. major surgery or major injury within 4 weeks before the first administration.

1. other cancers instead of ESCC

2. unresectable or metastatic ESCC

3. not comply with cⅡ-Ⅲ（cT2N1-2M0 or cT3N0-2M0, AJCC 8th）

4. Subjects with other malignant tumors within 5 years before the first administration, but subjects with cervical carcinoma in situ, skin basal cell carcinoma, skin squamous cell carcinoma, localized prostate cancer received radical surgery and ductal carcinoma in situ that have received radical treatment and do not need other treatment can be included)

3. Other criteria

1. Subjects have uncontrolled cardiovascular diseases, such as 1) heart failure ≥ NYHA class 2, 2) unstable angina 3) myocardial infarction within 1 year; 4) supraventricular or ventricular arrhythmia that needs treatment

2. Subjects with any known active autoimmune disease

3. Pregnant or breastfeeding female

4. Presence of allergy or hypersensitivity to investigational medications

5. HIV-positive or active hepatitis B (HBsAg positive and HBV-DNA ≥2000 IU/ml or ≥ 104 copies/mL) or active hepatitis C (HCV antibody positive) or active tuberculosis

6. Investigators assessed there might be other factors that cause subjects to withdraw.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Zhigang Li

OTHER

Sponsor Role: lead

Responsible Party

Zhigang Li

Chief of Department of Esophageal Surgery

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

Shanghai Chest Hospital

Shanghai, , China

Countries

China

Central Contacts

Zhigang Li, MD, PhD

Role: CONTACT

zhigang.li@shsmu.edu.com

86-18960619260

Zhichao Liu, MD, PhD

Role: CONTACT

zhichao.liu@sjtu.edu.cn

86-15622175948

Facility Contacts

Zhigang Li, MD, PhD

Role: primary

zhigang.li@shsmu.edu.com

18960619260

Other Identifiers

MA-EC-II-017

Identifier Type: -

Identifier Source: org_study_id